Hemogenyx Pharmaceuticals plc, a biopharma company group developing new therapies for blood diseases, has entered into a sponsored research agreement with the University of Pennsylvania to advance the CAR- T cells developed by the company (HEMO-CAR-T) toward clinical trials. The research is viewed as the first step of a larger program that hopes to achieve clinical proof of concept for HEMO-CAR-T for the treatment of acute myeloid leukemia (AML).